Focus: Venus MedTech is a China-based medical device company founded in 2024, specializing in transcatheter heart valve systems for aortic, pulmonary, and right ventricular outflow tract disorders. The company is early-stage with a focused cardiovascular pipeline and emerging commercial operations.
Profile data last refreshed 6h ago · AI intelligence enriched 1w ago
Growing — net +10 jobs in 30d
13 jobs added vs 3 removed. Steady team buildout.
Venus MedTech offers high-risk, high-upside entry to a nascent cardiovascular device company; best suited for early-career professionals seeking entrepreneurial environment and commercial execution experience over financial stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Venus MedTech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Venus MedTech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo